Media Center

On Wednesday, June 30, the Founder and CEO of TPIRC and Southern California Food Allergy Institute, Dr. Inderpal Randhawa, held a live webinar to talk about the different treatment options for children with food anaphylaxis. In case you missed it, you can watch the video here.

Disease-specific COVID-19 pediatric cases have not been studied effectively to date. Much is unknown as to how COVID-19 impacts children with pre-existing conditions, such as anaphylactic food allergies. Researchers at the Translational Pulmonary and Immunology Research Center (TPIRC), MemorialCare Heath System, Miller Children's Hospital and Irvine School of Medicine compiled and analyzed serum samples of food anaphylactic, asymptomatic children from across the United States to determine their risk of COVID-19 seropositivity. The report, titled “Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort”, was published in the international, peer-reviewed open access journal Antibodies by MDPI. Their data suggests that this specific population - food anaphylaxis and highly atopic children - are not at increased risk for COVID-19 than the general population.

The study used blood samples collected between February 1 and April 20, 2020 from children and adolescents, between the ages of 4 and 18 years, prior to treatment at the Translational Pulmonary Immunology Research Center (TPIRC) in California. All patients were enrolled as part of a food anaphylaxis treatment program. At the time of collection, all patients were asymptomatic of any acute disease process and had not received any form of food immunotherapy. All blood samples were reviewed and approved by the Advarra Institutional Review Board.

A total of 172 blood samples were tested for COVID-19, with positive results in six patients (4%) who had no symptoms at the time of the blood draw. This seropositivity rate of 4% is equal or less than the risk for the general population at the time of testing in the early months of the pandemic. This concludes that patient sensitivity to five common allergens - peanut, sesame, cashew, hazelnut, and pecan - did not significantly relate to COVID-19 positivity.

“The results of our study are reassuring for parents who have children with food allergies,” says Dr. Nathan Marsteller, Director of Research at the Translational Pulmonary and Immunology Research Center. “The anxiety and stress of living with a food allergy is overwhelming,” he continues, “so I am happy to find that this specific population appears at either equal or potentially less risk than the general population.”

A notable finding was increased IgG4 in the COVID-19 positive group, nearly three times that of the negative group. IgG4 may play a role as a biomarker in the local inflammatory environment, a factor in lung disease associated with COVID-19. The elevated serum IgG4 specific to viral infection risk is novel in this study and requires further research as a potential risk factor for COVID-19 infection.

A full copy of the study can be found here: https://www.mdpi.com/2073-4468/10/2/22/pdf

Our organization was approached by Esther Landhuis, an independent journalist, to write an article discussing the Tolerance Induction Program in the Summer of 2020. In the past, our organization has gladly allowed reporters to write about the processes and programs of the institute. Esther Landhuis visited our organization for a short half day tour of only a few of our five facilities. The journalist claims to be an immunologist and did not pursue questions focused on the complex immunological model of the Tolerance Induction Program. The article published on her behalf is unfortunately inaccurate in many dates, locations, and terms. Such a publication does not reflect the diligent, detailed work which is the Tolerance Induction Program.

The article interestingly critiques the institute and the Tolerance Induction Program from research universities and private allergists who state SoCal Food Allergy is secret about its process. The Tolerance Induction Program indeed involves trillions of data points, years of specific personnel training, and complex proprietary software support systems. Obviously, this type of system cannot be readily shared to classically trained physicians. This would be similar to allowing a surgeon access to a surgical robot without any training on the device. Nonetheless, the criticisms are not new. These entities have criticized the novel approach of TIP for years. These entities have not successfully treated food anaphylaxis patients to date. These entities, in addition, cannot demonstrate failures of the Tolerance Induction Program . The journalist spent over six months investigating TIP looking for failures. Clearly, the few stories represented do not reflect any new information. We maintain a well over 99% success rate in achieving remission.

What is clearly missing from this journalist's investigation is:

- SoCal Food Allergy and TPIRC being funded and grown by one Founder's monetary support
- Artificial Intelligence and Machine Learning Development model designs
- Multitude of regulatory agencies who govern TIP
- Extremely high safety rates
- Ability to maintain weekly dosing of sustained unresponsiveness
- Manufacturing facility production of dose specific proteins
- 24/7 on call support center
- Hundreds of biomarkers tested in our lab unavailable elsewhere
- Treatment of all patients, all complexities from around the US and the world.

Being on the cutting edge of medicine requires focus, dedication and gravitas to see every patient to the finish line. As long as our patients don't give up, we do not give up. The largest absence in the article are the thousands of successful patient stories which reflect our ultimate promise: remission from food anaphylaxis.

Inderpal Randhawa, MD
Founder, TPIRC + SoCal Food Allergy